12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

Genmab, J&J deal

Genmab will receive an $8 million milestone payment from Johnson & Johnson's Janssen Biotech Inc. unit under an August 2012 deal granting the unit exclusive, worldwide rights to daratumumab. Genmab said the milestone was...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >